Innoviva, Inc. (INVA) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| INVA | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | United States | United States |
| Theme | pharmaceuticals-large-cap | oncology |
| Price and returns | ||
| Last close | $21.05 | $123.96 |
| Return · 1 week | −0.14% | 0.00% |
| Return · 1 month | −0.85% | 0.00% |
| Return · 3 months | −3.48% | 0.00% |
| Return · year to date | +5.94% | +22.93% |
| Return · 1 year | +18.79% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −16.30% | −0.02% |
| 52-week high | $25.15 | $123.99 |
| 52-week low | $17.13 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $1.52B | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $14.24M | $149.69M |
| Employees | 159 | 234 |
| Valuation | ||
| Price to earnings · trailing | 4.96× | n/a (negative earnings) |
| Price to earnings · forward | 9.60× | n/a (negative forward earnings) |
| Price to sales | 3.48× | — |
| Price to book | 1.25× | 8.33× |
| Enterprise value to EBITDA | 6.52× | — |
| Enterprise value to revenue | 2.90× | — |
| PEG ratio | 3.11 | — |
| Earnings per share · trailing | 4.28 | -6.06 |
| Profitability | ||
| Gross margin | 78.17% | — |
| Operating margin | 43.28% | 0.00% |
| Profit margin | 81.19% | — |
| Return on equity | 36.68% | −41.19% |
| Return on assets | 6.95% | −22.51% |
| Growth | ||
| Revenue growth | +19.30% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 26.86 | — |
| Current ratio | 16.01 | 16.14 |
| Dividend yield | 0.00% | — |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 51.25 | — |
| ADX · 14 | 10.87 | — |
| 50-day average | $20.99 | — |
| 200-day average | $21.86 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.36% | — |
The full INVA analysis
Everything this table leaves out for Innoviva, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the INVA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full INVA analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis